Alder fleshes out timeline for migraine candidate

Alder Biopharmaceuticals Inc. (NASDAQ:ALDR) gained $7.04 (23%) to $37.23 on Friday after spelling out milestones expected next half for migraine candidate ALD403 during its 1Q15 earnings call.

Alder

Read the full 286 word article

How to gain access

Continue reading with a
two-week free trial.